Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

NORTHAMPTON, MA / ACCESS Newswire / February 19, 2025 / Take a spin through the latest in Gilead's science and innovation in our new series, The Centrifuge Sessions. Today we sit down with D. Barry ...

And there was.” Mandy, from Newcastle-under-Lyme in Staffordshire, was diagnosed with primary biliary cholangitis (PBC), a liver disease which causes liver failure. The condition also leaves ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Treatments for autoimmune hepatitis and primary biliary cirrhosis In both of these diseases, your body’s natural defense system (the immune system) attacks and damages your liver. Primary ...

"Scarring and liver cirrhosis from fatty liver disease. Viral causes include hepatitis A ... horrifying' sex attack "Autoimmune issues—such as autoimmune hepatitis, PBC, PSC. Take care of your liver ...

PBC is the most frequent CD-related liver disease, being regarded as the most prevalent autoimmune disorder detected in CD after Hashimoto thyroiditis, Type 1 diabetes mellitus and Sjogren syndrome.

For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications ...